Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 55

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 55
---
 90071(18) |     |                  |  8,896,223 |     |            |  9.1 | % |
| The Vanguard Group, 100 Vanguard Blvd., Malvern PA 19355(19)                               |     |                  |  8,816,124 |     |            |  9.0 | % |
| Shares Issued and Outstanding 4/8/2025                                                     |     |                  | 98,256,898 |     |            |      |   |

* Indicates beneficial ownership of one percent or less. (1) Except as otherwise indicated, the address of each stockholder identified is c/o Sarepta Therapeutics, Inc., 215 First Street, Cambridge, MA 02142. Except as indicated in the other footnotes to this table, each person named in this table has sole voting and investment power with respect to all shares of stock beneficially owned by that person. (2) Beneficial ownership is determined in accordance with rules of the SEC and generally includes voting or investment power with respect to securities. Shares of common stock subject to options currently exercisable or exercisable within 60 days as of April 8, 2025 are deemed beneficially owned and outstanding for computing the percentage of the person holding such securities, but are not considered outstanding for computing the percentage of any other person. (3) Includes 52,099 shares of our common stock subject to options exercisable within 60 days of April 8, 2025. (4) Includes 52,099 shares of our common stock subject to options exercisable within 60 days of April 8, 2025. (5) Includes 41,599 shares of our common stock subject to options exercisable within 60 days of April 8, 2025. (6) Includes 52,099 shares of our common stock subject to options exercisable within 60 days of April 8, 2025. (7) Includes 20,251 shares of our common stock subject to options exercisable within 60 days of April 8, 2025. (8) Includes 16,901 shares of our common stock subject to options exercisable within 60 days of April 8, 2025.

<div align='center'>32</div>

Includes 16,901 shares of our common stock subject to options exercisable within 60 days of April 8, 2025.

Includes 2,200,110 shares